Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Comparison of Glucagon Administered by Either the Nasal (LY900018) or Intra-muscular (GlucaGen®) Routes in Adult Patients With Type 1 Diabetes Mellitus During Controlled Insulin-Induced Hypoglycemia

Trial Profile

Comparison of Glucagon Administered by Either the Nasal (LY900018) or Intra-muscular (GlucaGen®) Routes in Adult Patients With Type 1 Diabetes Mellitus During Controlled Insulin-Induced Hypoglycemia

Completed
Phase of Trial: Phase I

Latest Information Update: 05 Oct 2018

At a glance

  • Drugs Glucagon (Primary) ; Glucagon (Primary)
  • Indications Hypoglycaemia
  • Focus Therapeutic Use
  • Sponsors Eli Lilly
  • Most Recent Events

    • 05 Oct 2018 Results of a primary efficacy analysis (n=66) presented at the 54th Annual Meeting of the European Association for the Study of Diabetes
    • 26 Jan 2018 Status changed from recruiting to completed.
    • 16 Nov 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top